Renalytix Plc (2O9)

Overview

Renalytix Plc is at the forefront of developing cutting-edge diagnostic solutions for kidney diseases, leveraging the power of artificial intelligence (AI) in the process. Established in 2018 and headquartered in New York, New York, the company concentrates on the intricate task of diagnosing and prognosticating kidney diseases through an innovative blend of AI, blood-based biomarkers, genetics, and electronic health records. Renalytix Plc, initially known as Renalytix AI plc, embraced its new name in June 2021 to perhaps reflect a broader aim and scale of operations. Through strategic partnerships with esteemed institutions like Mount Sinai Health System, Joslin Diabetes Center, Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine, Renalytix Plc is not just in the race of advancing kidney health diagnostics but also engaging in the development of more refined clinical care models for patients struggling with these conditions.

Products and Services

• KidneyIntelX

  The flagship product, KidneyIntelX, epitomizes the merger between technology and healthcare, standing as a pinnacle of Renalytix Plc's innovation. This diagnostic platform harnesses an AI-enabled algorithm that adeptly navigates through a plethora of data points—from validated blood-based biomarkers and genetic predispositions to comprehensive patient data extracted from electronic health records. The culmination of this intricate process is a unique patient risk score, tailor-made to forecast the progression of kidney disease with remarkable accuracy. KidneyIntelX's utility extends beyond mere diagnosis; it is instrumental in mapping out clinical care, stratifying patients for clinical trials, and even unlocking new drug discovery avenues by targeting kidney disease on a molecular level.

• Strategic Partnerships for Clinical Care and Research

  Renalytix Plc’s collaboration spectrum is broad, encompassing esteemed entities like the Mount Sinai Health System, Joslin Diabetes Center, Inc., Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine. These alliances are not just for brandishing the company's portfolio but are significantly aimed at the development and commercialization of AI-driven diagnostic and prognostic solutions for kidney diseases. Each partnership brings a unique strength to the table, from refining diagnostic precision with Mount Sinai and Joslin Diabetes Center to crafting advanced clinical care models with Atrium Health and Wake Forest entities. These partnerships amplify Renalytix Plc's mission to mitigate kidney disease progression and minimize the risk of kidney failure in affected patients by implementing more advanced, data-driven clinical care paradigms.